Core Points - The stock price of Sangfor Technologies increased by 5.19% to 58.35 CNY per share, with a trading volume of 210 million CNY and a turnover rate of 0.60%, resulting in a total market capitalization of 35.989 billion CNY [1] - Sangfor Technologies, established on January 25, 2002, and listed on July 22, 2020, is primarily engaged in the research, production, and sales of antibody drugs, with revenue sources including 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing, and 1.44% from leasing services [1] Shareholder Insights - Industrial and Commercial Bank of China (ICBC) Credit Suisse Fund's "ICBC Frontier Medical Stock A" increased its holdings by 601,000 shares in the third quarter, now holding 3.8 million shares, which represents 0.62% of the circulating shares [2] - The fund has achieved a year-to-date return of 25.16%, ranking 2300 out of 4218 in its category, and an annual return of 18.28%, ranking 2670 out of 3878 [2] - The fund manager, Zhao Bei, has a tenure of 10 years and 348 days, with a total fund asset size of 17.15 billion CNY and a best return of 224.6% during her tenure [2]
三生国健股价涨5.19%,工银瑞信基金旗下1只基金位居十大流通股东,持有380万股浮盈赚取1094.4万元